MiReven Receives Further $500K from MRCF
News Sep 15, 2012
MiReven has announced that it had received a further AU$500K investment from the Medical Research Commercialization Fund (MRCF) due to the successful completion of various technical and commercial milestones.
This brings the total that the MRCF has invested in MiReven since its foundation in 2010 to AU$1.1M.
MiReven has recently signed two international R&D collaborations to investigate the therapeutic efficacy of systemically delivered miR-7 in several different cancer models, thereby strengthening the potential of miR-7 as a treatment for cancer.
The first agreement is with Silence Therapeutics, announced on August 22, to use Silence’s proprietary AtuPLEX™ and DACC delivery systems to evaluate miR-7 in various cancer models. Silence will formulate a miR-7 mimetic and then use it to undertake in vitro and in vivo studies.
An important second deal, signed with another undisclosed international company, takes a similarly strategic approach to positioning miR-7 as a cancer therapeutic.
Dr Stephen Thompson, Chairman of MiReven Pty Ltd, said: “We are thrilled with our progress at MiReven. This pivotal funding from the MRCF allows MiReven to expand and undertake in vivo studies to examine the delivery of miR-7 with independent parties. The deal with Silence Therapeutics is particularly important to us as it is critically important to the development of microRNA drugs to find the right delivery method so that they can reach important cancer targets. Looking to the future, once these studies are complete, we aim to identify a development partner to take miR-7 into the clinic.”
Dr Chris Nave, Principal Executive of the MRCF commented: “MRCF is delighted to be once again backing the world class discoveries from WAIMR. In particular we would also like to thank the Western Australian government for its ongoing support of the MRCF.”
Professor Peter Klinken, Director of the WAIMR, added: "Congratulations to Peter Leedman and his WAIMR team for their exciting achievements, which have been made possible by the vision and invaluable support of the State, UWA and MRCF. The investment from all stakeholders is not only helping to commercialize WA created innovation, but also supporting high tech jobs and some of our brightest young medical researchers."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018